ImmunityBio Logo
US45256X1037
A2QQ2E
IBRX

ImmunityBio

Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 13,68 € (+129,92 %). La médiane est de 13,68 € (+129,92 %).

Acheter
  5
Conserver
  0
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • ImmunityBio stock rises after ANKTIVA approval in the UAE

    ImmunityBio shares climbed 7.5% after ANKTIVA was approved in the United Arab Emirates. The approval covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive, non‑muscle‑invasive bladder cancer and ANKTIVA 1.2 mg with immune checkpoint inhibitors for metastatic non‑small‑cell lung cancer. The approval expands ANKTIVA’s regulatory presence to 34 countries and is based on the QUILT‑3.032 study (in NMIBC: 71% complete response rate in the CIS cohort; 12‑month DFR 58.2% in papillary tumors; 83% cystectomy‑free at 36 months) and QUILT‑3.055 (in checkpoint‑refractory NSCLC: median overall survival 14.6 months). » Plus sur de.investing.com


  • ImmunityBio analysis: ANKTIVA plus BCG significantly more cost-effective than TAR-200 in bladder cancer

    A health economic analysis presented in Philadelphia shows that ANKTIVA combined with BCG achieves substantial cost savings over three years compared with TAR-200 for BCG-unresponsive, non–muscle-invasive bladder cancer. Savings per avoided cystectomy were $109,622 in year 1, $151,438 in year 2 and $60,393 in year 3; savings per cystectomy-free month were $9,370, $6,144 and $1,520 in years 1–3, respectively. The study attributed the cost reductions to lower acquisition and administration costs and slightly higher complete response rates (49.6% vs. 45.9%). Investors reacted positively; the stock has returned 272% in the past six months and is trading at $7.74. » Plus sur de.investing.com


  • ImmunityBio obtains exclusive US rights to Tokio-172 BCG

    ImmunityBio has signed an exclusive development and supply agreement with Japan BCG Laboratory for the Tokio-172 BCG strain in the U.S. and could become the sole BLA applicant. The decision is based on Phase III SWOG S1602 data showing non-inferiority to TICE BCG (HR 0.82) and an estimated 5-year recurrence-free survival of 64% vs. 58%. Tokio-172 is not yet FDA-approved in the U.S.; ImmunityBio is in discussions with the FDA and research institutions about data use and plans regulatory steps. The company reports strong revenue growth but remains unprofitable, and analysts see further upside potential despite recent share gains. » Plus sur de.investing.com


  • ImmunityBio posts strong Anktiva sales growth and expands global access

    ImmunityBio reported accelerating commercial traction for Anktiva with Q4 2025 net product revenue up 700% year‑over‑year and unit volumes rising 750%, driven by broadened physician and patient adoption. The company has expanded Anktiva access to 33 countries across four major regulatory jurisdictions and secured an FDA J‑code to improve reimbursement visibility. ImmunityBio is advancing a multi‑layered immunotherapy platform—Anktiva (IL‑15 superagonist), NaNT allogeneic cell therapy, DNA vaccines and Leonardo manufacturing for off‑the‑shelf NK/CAR‑NK products—that management says could scale into an API‑like personalized immune regimen and materially re‑rate the company if execution continues. Continued commercial momentum and regulatory tailwinds underpin a bullish long‑term thesis for IBRX, albeit with execution risk. » Plus sur finance.yahoo.com


  • ImmunityBio posts 168% y/y product revenue jump as ANKTIVA launch gains traction

    ImmunityBio reported preliminary results for the quarter ending March 31, 2026, with product revenue rising 168% year over year to $44.2 million following the commercial launch of ANKTIVA. The company recorded $113 million net product revenue in 2025 (up 700% from 2024) and ended the quarter with $380.9 million in cash and cash equivalents. ANKTIVA has regulatory approval across five jurisdictions covering 34 countries, and ImmunityBio is focused on scaling U.S. commercialization and global expansion to broaden revenue streams. » Plus sur finance.yahoo.com

En 2026, ImmunityBio a déjà versé 0,0574 € de dividendes. Le dernier versement a eu lieu en juin.

Données financières de l'entreprise

Au dernier trimestre, ImmunityBio a réalisé un chiffre d'affaires de 43,12 M € et un bénéfice net de -162,93 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 43,12 M 57,83 %
Bénéfice brut 41,98 M 76,37 %
Bénéfice net -162,93 M 184,30 %
EBITDA -131,24 M 330,53 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
6,07 Md €
Nombre d'actions
1,06 Md
Plus haut/bas sur 52 semaines
11,33 € - 1,78 €
Rendement du dividende
1,05 %
Dividendes TTM
0,0574 €
Bêta
0,13
Ratio P/E
-5,84
Ratio PEG
0,05
Ratio P/B
-5,79
Ratio P/S
36,48

Profil de l'entreprise

ImmunityBio, Inc., une société de biotechnologie au stade clinique, développe des thérapies et des vaccins destinés au traitement des cancers et des maladies infectieuses. Elle propose des plateformes d'immunothérapie et de thérapie cellulaire, notamment des protéines de fusion anticorps-cytokines, des immunomodulateurs synthétiques, des technologies vaccinales, des cellules tueuses naturelles (NK) et des systèmes immunitaires adaptatifs (lymphocytes T). La société développe également des agents thérapeutiques en essais cliniques de phase II ou III pour le traitement de tumeurs liquides et solides, notamment les cancers de la vessie, du pancréas et du poumon, ainsi que des agents pathogènes tels que le SARS-CoV-2 et le VIH. Elle a conclu des accords de collaboration avec le National Cancer Institute, le National Institute of Deafness and Communication Disorders et Amyris, Inc. ; et des accords de licence avec CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc. et Viracta Therapeutics, Inc. La société a été fondée en 2014 et son siège se trouve à San Diego, en Californie.

Nom
ImmunityBio
PDG
Richard Gerald Adcock
Siège social San Diego, ca
États-Unis
Site web
Secteur
Santé
Industrie
Biotechnologie
Introduction en bourse
28/07/2015
Employés 688

Symboles boursiers

Bourse Symbole
NASDAQ
IBRX
Frankfurt
26CA.F
Düsseldorf
26CA.DU
München
26CA.MU
🍪

Parqet  utilise des cookies. En savoir plus